The Role of Nuclear Factor Kappa B (NF-κB) in Development and Treatment of COVID-19: Review

Int J Mol Sci. 2022 May 9;23(9):5283. doi: 10.3390/ijms23095283.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes Coronavirus Disease 19 (COVID-19), a disease that has affected more than 500 million people worldwide since the end of 2019. Due to its high complications and death rates, there is still a need to find the best therapy for SARS-CoV-2 infection. The dysregulation of the inflammatory response in COVID-19 plays a very important role in disease progression. It has been observed that abnormal activity of Nuclear Factor kappa B (NF-κB) is directly associated with, inter alia, increased synthesis of proinflammatory factors. Therefore, this review paper focuses on the functions of NF-κB in the development of SARS-CoV-2 infection and potential application of NF-κB inhibitors in COVID-19 immunotherapy. A comprehensive literature search was performed using the MEDLINE/PubMed database. In the current review, it is highlighted that NF-κB plays important functions in the modulation of an adaptive inflammatory response, including inducing the expression of proinflammatory genes. Increased activation of NF-κB in SARS-CoV-2 infection was observed. The association between NF-κB activation and the expression of SARS-CoV-2 structural and non-structural proteins were also reported. It was observed that modulation of NF-κB using, e.g., traditional Chinese medicine or glucocorticosteroids resulted in decreased synthesis of proinflammatory factors caused by SARS-CoV-2 infection. This review summarizes the role of NF-κB in COVID-19 and describes its potential immunotherapeutic target in treatment of SARS-CoV-2 infection. However, indisputably more studies involving patients with a severe course of COVID-19 are sorely needed.

Keywords: COVID-19; Nuclear Factor kappa B (NF-κB); SARS-CoV-2; inflammation; inflammatory factors.

Publication types

  • Review

MeSH terms

  • COVID-19 / immunology
  • COVID-19 / pathology*
  • COVID-19 Drug Treatment
  • Humans
  • Inflammation / pathology
  • NF-kappa B / metabolism*
  • SARS-CoV-2

Substances

  • NF-kappa B

Grants and funding

This research was supported by the Medical University of Bialystok, Poland.